Quest for the right Drug
מולקולות חדשות
מינירין טבליות 0.2 מ"ג MINIRIN TABLETS 0.2 MG
תאריך רישום: October 22, 2009
מסלול הגשה: מולקולה חדשה
יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND
בעל רישום: FERRING PHARMACEUTICALS LTD
H01BA02 :ATC Code
4.1 Therapeutic indications Minirin tablets are indicated for Central Diabetes Insipidus, Nocturnal Enuresis (in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started before the age of 65.
לדף התרופה >מינירין טבליות 0.1 מ"ג MINIRIN TABLETS 0.1 MG
תאריך רישום: October 22, 2009
מסלול הגשה: מולקולה חדשה
יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND
בעל רישום: FERRING PHARMACEUTICALS LTD
H01BA02 :ATC Code
4.1 Therapeutic indications Minirin tablets are indicated for Central Diabetes Insipidus, Nocturnal Enuresis (in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started before the age of 65.
לדף התרופה >היקמטין 1 מ"ג HYCAMTIN 1 MG
תאריך רישום: June 5, 2008
מסלול הגשה: מולקולה חדשה
יצרן: ANALYTISCHES ZENTRUM BIOPHARM GMBH BERLIN, GERMANY
בעל רישום: SANDOZ PHARMACEUTICALS ISRAEL LTD
L01XX17 :ATC Code
4.1 Therapeutic indications HYCAMTIN capsules are indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
לדף התרופה >טאלווי 2 מ"ג/מ"ל TALVEY 2 MG/ML
תאריך רישום: November 8, 2023
מסלול הגשה: מולקולה חדשה
יצרן: ANDERSONBRECON INC., USA
בעל רישום: J-C HEALTH CARE LTD
L01FX29 :ATC Code
4.1 Therapeutic indications TALVEY is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
לדף התרופה >טאלווי 40 מ"ג/מ"ל TALVEY 40 MG/ML
תאריך רישום: November 8, 2023
מסלול הגשה: מולקולה חדשה
יצרן: ANDERSONBRECON INC., USA
בעל רישום: J-C HEALTH CARE LTD
L01FX29 :ATC Code
4.1 Therapeutic indications TALVEY is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
לדף התרופה >מנקוודפי MENQUADFI
תאריך רישום: December 1, 2022
מסלול הגשה: מולקולה חדשה
יצרן: SANOFI PASTEUR INC., USA
בעל רישום: SANOFI ISRAEL LTD
J07AH02 :ATC Code
